(Alliance News) - MGC Pharmaceuticals Ltd on Monday announced positive pre-clinical trial results from a pre-clinical chronic toxicology evaluation of a 14-day oral dose of CimetrA.
CimetrA is a nanoparticle micellar formulation. It has demonstrated anti-inflammatory and immunomodulating effects in previous clinical trials.
In the recently completed study, undertaken on 32 pigs receiving a study treatment for 14 days, CimetrA was found to be safe. The histopathological analysis of the full organs spectrum demonstrated all tissues of all the animals were normal and unaffected.
It was concluded that the test at the dosage administered did not induce toxicological changes. No changes in the blood and urine samples were reported.
Roby Zomer, chief executive and managing director at MGC said: "We are delighted with the positive clinical trial results for CimetrA which paves the way for our [investigational new drug] submission to the [US Food & Drug Administration] next year. The potential addressable market for our anti-inflammatory and immunomodulating product is considerable and this represents a key milestone for the business."
MGC Pharmaceuticals is a pharmaceutical company specialising in the production and development of plant derived medicines. Its corporate headquarters is in London.
Shares in the firm were up 10% at 0.15 pence on Monday morning in London.
By Heather Rydings, Alliance News senior economics reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.